[Fresolimumab: A new treatment option for systemic scleroderma on the horizon?], PMID: 26391323
89 Zr-Labeled fresolimumab (human anti-transforming growth factor-β monoclonal antibody), PMID: 22299190
A Functional Genomic Meta-Analysis of Clinical Trials in Systemic Sclerosis: Toward Precision Medicine and Combination Therapy, PMID: 28011145
A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis, PMID: 21368745
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis, PMID: 29270487
Antibody targeting of TGF-β in cancer patients, PMID: 21619535
Antibody-based therapies for idiopathic pulmonary fibrosis, PMID: 32098521
Anti-transforming growth factor-β therapy in patients with myelofibrosis, PMID: 23682558
Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients, PMID: 31296256
Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008), PMID: 25579378
Discovery of Selective Transforming Growth Factor β Type II Receptor Inhibitors as Antifibrosis Agents, PMID: 34055221
Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer, PMID: 29476019
Focal segmental glomerulosclerosis: molecular genetics and targeted therapies, PMID: 26156092
Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients, PMID: 26098215
Gateways to clinical trials, PMID: 20140276
Immunotherapy of systemic sclerosis, PMID: 29985736
Metastasis and the Tumor Microenvironment: A Joint Metastasis Research Society-AACR Conference - Research on Metastasis: part 2, PMID: 21046523
Monoclonal antibodies for renal diseases: current concepts and ongoing treatments, PMID: 26087994
Novel TGF- β inhibitors ready for prime time in onco-immunology, PMID: 28197376
PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models, PMID: 22072706
Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma, PMID: 24618589
Positron Emission Tomography Imaging of Functional Transforming Growth Factor β (TGFβ) Activity and Benefit of TGFβ Inhibition in Irradiated Intracranial Tumors, PMID: 33007434
Recent advances in the treatment of skin involvement in systemic sclerosis, PMID: 29259711
Recent Advances in Treatments of Primary Focal Segmental Glomerulosclerosis in Children, PMID: 27195285
Structures of a pan-specific antagonist antibody complexed to different isoforms of TGFβ reveal structural plasticity of antibody-antigen interactions, PMID: 25209176
Targeted Therapy in Systemic Sclerosis, PMID: 27824545
Targeting TGF-β Signaling in Kidney Fibrosis, PMID: 30150520
TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET, PMID: 26135113
TGFβ-Directed Therapeutics: 2020, PMID: 32835827
Treatment of idiopathic focal segmental glomerulosclerosis: options in the event of resistance to corticosteroids and calcineurin inhibitors, PMID: 23897176
Predictive biomarkers for response to TGF- β inhibition in resensitizing chemo(radiated) esophageal adenocarcinoma., PMID:39059615
Current and Developing Pharmacologic Agents for Improving Skeletal Health in Adults with Osteogenesis Imperfecta., PMID:38472351
In-silico prediction of TGF-β1 non-synonymous variants and their impact on binding affinity to Fresolimumab., PMID:37817532
Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses., PMID:35858707
Interventions for focal segmental glomerulosclerosis in adults., PMID:35224732
Targeting TGF-β for treatment of osteogenesis imperfecta., PMID:35113812
Discovery of Selective Transforming Growth Factor β Type II Receptor Inhibitors as Antifibrosis Agents., PMID:34055221
Positron Emission Tomography Imaging of Functional Transforming Growth Factor β (TGFβ) Activity and Benefit of TGFβ Inhibition in Irradiated Intracranial Tumors., PMID:33007434
TGFβ-Directed Therapeutics: 2020., PMID:32835827
Antibody-based therapies for idiopathic pulmonary fibrosis., PMID:32098521
Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients., PMID:31296256
Targeting TGF-β Signaling in Kidney Fibrosis., PMID:30150520
Immunotherapy of systemic sclerosis., PMID:29985736
Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer., PMID:29476019
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis., PMID:29270487
Recent advances in the treatment of skin involvement in systemic sclerosis., PMID:29259711
Novel TGF-β inhibitors ready for prime time in onco-immunology., PMID:28197376
A Functional Genomic Meta-Analysis of Clinical Trials in Systemic Sclerosis: Toward Precision Medicine and Combination Therapy., PMID:28011145
Targeted Therapy in Systemic Sclerosis., PMID:27824545
Recent Advances in Treatments of Primary Focal Segmental Glomerulosclerosis in Children., PMID:27195285
[Fresolimumab: A new treatment option for systemic scleroderma on the horizon?]., PMID:26391323
Focal segmental glomerulosclerosis: molecular genetics and targeted therapies., PMID:26156092
TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET., PMID:26135113
Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients., PMID:26098215
Monoclonal antibodies for renal diseases: current concepts and ongoing treatments., PMID:26087994
Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008)., PMID:25579378
Structures of a pan-specific antagonist antibody complexed to different isoforms of TGFβ reveal structural plasticity of antibody-antigen interactions., PMID:25209176
Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma., PMID:24618589
Treatment of idiopathic focal segmental glomerulosclerosis: options in the event of resistance to corticosteroids and calcineurin inhibitors., PMID:23897176
Anti-transforming growth factor-β therapy in patients with myelofibrosis., PMID:23682558
PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models., PMID:22072706
Antibody targeting of TGF-β in cancer patients., PMID:21619535
A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis., PMID:21368745
Metastasis and the Tumor Microenvironment: A Joint Metastasis Research Society-AACR Conference - Research on Metastasis: part 2., PMID:21046523
Gateways to clinical trials., PMID:20140276
For research use only. Not for human or drug use.
